Influenza B Infections - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 40 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Influenza B Infections - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Influenza B Infections - Pipeline Review, H1 2015', provides an overview of the Influenza B Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Influenza B Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Influenza B Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Influenza B Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Influenza B Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Influenza B Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Influenza B Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Influenza B Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Influenza B Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Influenza B Infections Overview 6
Therapeutics Development 7
Pipeline Products for Influenza B Infections - Overview 7
Pipeline Products for Influenza B Infections - Comparative Analysis 8
Influenza B Infections - Therapeutics under Development by Companies 9
Influenza B Infections - Therapeutics under Investigation by Universities/Institutes 10
Influenza B Infections - Pipeline Products Glance 11
Early Stage Products 11
Influenza B Infections - Products under Development by Companies 12
Influenza B Infections - Products under Investigation by Universities/Institutes 13
Influenza B Infections - Companies Involved in Therapeutics Development 14
AltraVax Inc. 14
Chimerix, Inc. 15
ContraFect Corporation 16
Crucell N.V. 17
Humabs BioMed SA 18
REPLICor Inc. 19
Influenza B Infections - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 26
Drug Profiles 28
AL-18 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
CF-403 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
CR-8033 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
CR-8071 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CR-9114 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Monoclonal Antibody for Influenza B Infections - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
REP-9 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
seasonal influenza B vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecules for Influenza B - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Influenza B Infections - Dormant Projects 37
Influenza B Infections - Product Development Milestones 38
Featured News & Press Releases 38
Mar 11, 2011: Sanofi Pasteur And Daiichi Sankyo Announce Voluntary Recall Of Hemophilus Influenza Type B Conjugate Vaccine 38
Apr 23, 1993: FDA Approval of Use of a New Haemophilus b Conjugate Vaccine and a Combined Diphtheria-Tetanus-Pertussis and Haemophilus b Conjugate Vaccine for Infants and Children 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Tables
Number of Products under Development for Influenza B Infections, H1 2015 7
Number of Products under Development for Influenza B Infections - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Products under Development by Companies, H1 2015 12
Products under Investigation by Universities/Institutes, H1 2015 13
Influenza B Infections - Pipeline by AltraVax Inc., H1 2015 14
Influenza B Infections - Pipeline by Chimerix, Inc., H1 2015 15
Influenza B Infections - Pipeline by ContraFect Corporation, H1 2015 16
Influenza B Infections - Pipeline by Crucell N.V., H1 2015 17
Influenza B Infections - Pipeline by Humabs BioMed SA, H1 2015 18
Influenza B Infections - Pipeline by REPLICor Inc., H1 2015 19
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Stage and Target, H1 2015 22
Number of Products by Stage and Mechanism of Action, H1 2015 24
Number of Products by Stage and Route of Administration, H1 2015 25
Number of Products by Stage and Molecule Type, H1 2015 27
Influenza B Infections - Dormant Projects, H1 2015 37